Annovis Bio, Inc. (ANVS)

The investment case here is a stark dichotomy between a catastrophic long-term reality and a speculative short-term gamble. Fundamentally, the business is in freefall; the stock has lost 55% of its value over the last five years, with four consecutive years of negative annual returns. The company is burning cash, posting negative returns on equity and assets, and recently raised capital through a dilutive stock offering that sent shares tumbling. There is no dividend to provide income, and the balance sheet offers no fortress-like protection against continued losses. However, the options market tells a completely different story for the immediate future. Traders are positioning aggressively for a massive upside move, with heavy open interest in deep out-of-the-money calls while virtually ignoring put protection. This flow aligns with the recent news of full enrollment in a pivotal Phase 3 Alzheimer's trial. The market is pricing in a binary outcome: either the trial succeeds and the stock rallies exponentially, or it fails and the speculative premium evaporates. For a traditional investor, the deteriorating fundamentals and lack of dividends make this a 'avoid' rating. But for a trader willing to accept the risk of total loss for a chance at a lottery-ticket payoff, the options flow suggests a high-conviction bet on a positive catalyst in the coming weeks.